UTI
Universal Technical Institute, Inc.
UTI's fundamentals are weak: its operating margin fell 5 points to 5% and earnings per share fell 47%, though revenue grew 9.1%. At 36x earnings, it's trading in line with its usual 34x. Analysts expect strong earnings growth.
UTI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Healthy |
UTI's balance sheet is currently healthy, and its revenue and profitability are stable, but its cash flow is under pressure.
UTI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 20x | $12.41 | -44% |
| Forward | 31x | $22.18 | — |
| Fair | 34x | $20.81 | -6.2% |
| Current | 36x | $22.18 | — |
| Expensive | 82x | $49.93 | +125% |
Historical ranges are pointers, not guarantees.
UTI's PE is in its fair range at 36x. If earnings grow as analysts expect, today's price would be 31x next year's earnings.
UTI Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for UTI, with profitability improving.
UTI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.71 | +17% |
| Q2 2026 | $0.61 | -47% |
| Q1 2026 | $0.76 | -28% |
| Q4 2025 | $0.96 | -2% |
| Q3 2025 | $1.13 | +51% |
| Q2 2025 | $1.15 | +121% |
| Q1 2025 | $1.05 | +176% |
| Q4 2024 | $0.98 | +250% |
| Q3 2024 | $0.75 | +477% |
UTI's earnings per share have fallen from their peak: $0.61 over the past year, against $1.15 in mid-2025.
UTI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $218.9M | +7.2% |
| Q1 2026 | $221.4M | +6.7% |
| Q4 2025 | $220.8M | +9.6% |
| Q3 2025 | $222.4M | +13% |
| Q2 2025 | $204.3M | +15% |
| Q1 2025 | $207.4M | +13% |
| Q4 2024 | $201.4M | +15% |
| Q3 2024 | $196.4M | +15% |
UTI's revenue has grown year over year for 21 quarters in a row: $219M last quarter, up 7.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 1.5% | -5.4 points |
| Q1 2026 | 0.1% | -8 points |
| Q4 2025 | 7.1% | -6.5 points |
| Q3 2025 | 11% | -2 points |
| Q2 2025 | 6.9% | +2.7 points |
| Q1 2025 | 8.1% | +2 points |
| Q4 2024 | 14% | +5.5 points |
| Q3 2024 | 13% | +7.2 points |
UTI's operating margin was 1.5% last quarter, down 5.4 points from the same quarter a year ago.
UTI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$17.9M | -362% |
| Q1 2026 | -$26.4M | -$14.7M |
| Q4 2025 | -$19.2M | -198% |
| Q3 2025 | $40.6M | -32% |
| Q2 2025 | $6.8M | +128% |
| Q1 2025 | -$11.7M | -$3.3M |
| Q4 2024 | $19.6M | +181% |
| Q3 2024 | $60M | +30% |
UTI's free cash flow was −$23M over the past year, against $75M the year before.
UTI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +205K shares |
| 1 year | +0.5% | +300K shares |
| 3 years | +64% | +21.9M shares |
| 5 years | +69% | +22.9M shares |
| Available history | +120% | +30.5M shares |
UTI has 56M diluted shares, up 0.5% from a year ago.
UTI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.4x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | -0.4x | Net Cash |
| Q2 2025 | 0.0x | Very low |
| Q1 2025 | -0.0x | Net Cash |
| Q4 2024 | -0.5x | Net Cash |
| Q3 2024 | -0.4x | Net Cash |
UTI's net debt is less than a year of its operating earnings (EBITDA).
UTI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.3 | Neutral |
| Stochastic | 21.4 | Neutral |
UTI's weekly RSI is 41 (neutral) and its Stochastic is 21 (neutral).
UTI PE vs Consumer Defensive Sector
| Metric | UTI | Sector median | Relative |
|---|---|---|---|
| PE | 36x | 19x | 87% above |
| PE % | 53 | 18 | 35 pts above |
UTI is trading at 36x earnings, a 87% premium to the Consumer Defensive sector's median of 19x.
UTI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.9 | 5.9% above |
| 20 week MA | $27.2 | 18% below |
| 50 week MA | $31.0 | 28% below |
| 100 week MA | $30.0 | 26% below |
| 200 week MA | $21.2 | 4.7% above |
UTI's trend is mixed: it's above two of its five weekly moving averages, and 4.7% above its 200-week average.
UTI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.25 | $6.38 | -12% |
| 2021 | $6.38 | $7.72 | +21% |
| 2022 | $7.72 | $6.15 | -20% |
| 2023 | $6.15 | $12.5 | +104% |
| 2024 | $12.5 | $26.0 | +107% |
| 2025 | $26.0 | $27.3 | +5.2% |
| 2026 YTD | $27.3 | $22.2 | -19% |
UTI has finished higher in four of the last six years, two of them by more than 50%. It's down 19% so far in 2026.